Brief: FDA Grants Orphan Drug Tag to NeoImmuneTech's Acute Radiation Syndrome Treatment
20/11/2023 11:53
Nov 20 (Reuters) - Neoimmunetech Inc 950220.KQ :
* NEOIMMUNETECH INC -
* FDA GRANTS ORPHAN DRUG DESIGNATION TO NEOIMMUNETECH'S
NT-I7 FOR
TREATMENT OF ACUTE RADIATION SYNDROME
Source text for Eikon: ID:nPn8N0dsDa
Further company coverage: 950220.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neoimmunetech
See all newsBrief: Emmaus Life Sciences Enters License And Distribution Agreement With Neoimmunetech
Brief: Neoimmunetech To Conduct Capital Increase Of 65 Billion Won For Operational Funds
Brief: FDA Grants Orphan Drug Designation Status To NeoImmuneTech's NT-I7 For Advanced Pancreatic Cancer Treatment
Brief: FDA Grants Orphan Drug Tag to NeoImmuneTech's Acute Radiation Syndrome Treatment
Brief: Neoimmunetech Presents Phase 1 Study Data At Society For Neuro-Oncology Annual Meeting